Sage Journals: Discover world-class research

Open access

Editorial

First published 2017-12

Are the Ethical Committees for Pharmacological Research Bureaucratic Bodies?

Bruno Mario Cesana

Journal of Public Health Research

Free access

Research article

First published 1972-07

Committees of Society of Pharmacological and Environmental Pathologists

Toxicologic Pathology

Retricted access

Research article

First published 2025-10

Treatment recommendations for the systemic pharmacological treatment of systemic sclerosis digital ulcers: Results from the World Scleroderma Foundation Ad Hoc Committee

Nancy Maltez, Laura Ross, Murray Baron [...]

Journal of Scleroderma and Related Disorders

Retricted access

Research article

First published 1990-7

FDA Perspective on Computer Assisted Pharmacology/Toxicology Review

Michael R. Hamrell

Therapeutic Innovation & Regulatory Science

Retricted access

Research article

First published 1998-4

Are Safety Committees Really Safe?

D. Bergqvist, C.D. Forbes, C.E. Minder [...]

Scottish Medical Journal

Retricted access

Other

First published 2003-09

Development of Diagnostic Criteria for Defining Sleep Disturbance in Alzheimer's Disease

Jerome A. Yesavage, Leah Friedman, Sonia Ancoli-Israel [...]

Journal of Geriatric Psychiatry and Neurology

Retricted access

Research article

First published 1997-7

Voluntary Standards for the Operation of Clinical Pharmacology Units

Gary L. Steinman, Susana R. K. de Dennis, Albert J. Dietz [...]

Therapeutic Innovation & Regulatory Science

Retricted access

Research article

First published 2021-6

Testing Meldonium: Assessing Soviet pragmatic alternatives to the randomized controlled trial

Anastasiya Chirkova, Alexander Petrenko, Pavel Vasilyev

Clinical Trials

Retricted access

In brief

First published 1996-7

The Drug Utilization Review Network of Quebec

Marie-Claude Breton, With the Scientific Committee of the Drug Utilization Review Network, Members of the Scientifc Committee of the RRUM include

Healthcare Management Forum

Retricted access

Other

First published 1993-10

Risk/Benefit Assessment of New Drugs: Perspectives of a Former FDA Advisory Committee Member

James H. Lewis

Therapeutic Innovation & Regulatory Science

Search results